INT141179

Context Info Confidence 0.41 First Reported 2007 Last Reported 2010 Negated 1 Speculated 0 Reported most in Body Documents 2 Total Number 2 Disease Relevance 1.53 Pain Relevance 1.14

cytosol (Apaf1) Golgi apparatus (Apaf1) nucleus (Apaf1) intracellular (Apaf1) cytoplasm (Apaf1)

Apaf1 (Mus musculus)

Pain Link Frequency Relevance Heat Eae 6 99.88 allodynia 1 99.38 Thermal hyperalgesia 1 98.88 Spinal cord 5 90.00 Sciatic nerve 3 87.76 Dorsal horn 2 84.96 Neuropathic pain 4 79.56 Pain 3 25.00 imagery 3 5.00 cerebral cortex 2 5.00

Disease Link Frequency Relevance Heat Injury 6 99.88 Neuropathic Pain 5 99.38 Hyperalgesia 1 98.88 Apoptosis 7 97.28 Neurodegenerative Disease 7 59.12 Disease 5 38.56 Microcephaly 6 5.00 Syndrome 6 5.00 Chromosome Breakage 5 5.00 Breast Cancer 4 5.00

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

Administration of phenyl-N-tert-butylnitrone (PBN), a potent ROS scavenger, reduced the development of thermal hyperalgesia and mechanical allodynia at 1 and 3 days post-CCI, and decreased the mRNA levels of bax, apaf-1, and caspase-9.

Negative_regulation (decreased) of apaf-1 associated with allodynia, eae and thermal hyperalgesia

1) Confidence 0.41 Published 2007 Journal Pharmacol. Res. Section Abstract Doc Link 17207636 Disease Relevance 1.42 Pain Relevance 1.14

More specifically, there was no significant reduction in the expression levels of Chk1, Brca1, Topbp1, Rad51, Ddb2, p73, Apaf1, or caspases which were all described to show reduced expression following MCPH1 knockdowns [34] (Tables S3, S4, S5).

Neg (no) Negative_regulation (reduction) of Apaf1

2) Confidence 0.24 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2821930 Disease Relevance 0.12 Pain Relevance 0

General Comments

This test has worked.